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Abstract
Background/Aims Hematocrit is a widely used biomarker to guide early fluid therapy for patients with acute pancreatitis 
(AP), but there is controversy over whether early rapid fluid therapy (ERFT) should be used in hemoconcentrated patients. 
This study investigated the association of hematocrit and ERFT with clinical outcomes of patients with AP.
Methods Data from prospectively maintained AP database and retrospectively collected fluid management details were 
stratified according to actual severity defined by revised Atlanta classification. Hemoconcentration and “early” were defined 
as hematocrit > 44% and the first 6 h of general ward admission, respectively, and “rapid” fluid rate was defined as ≥ 3 ml/
kg/h. Patients were allocated into 4 groups for comparisons: group A, hematocrit ≤ 44% and fluid rate < 3 ml/kg/h; group 
B, hematocrit ≤ 44% and fluid rate ≥ 3 ml/kg/h; group C, hematocrit > 44% and fluid rate < 3 ml/kg/h; and group D, hema-
tocrit > 44% and fluid rate ≥ 3 ml/kg/h. Primary outcome was rate of noninvasive positive-pressure ventilation (NPPV).
Results A total of 912 consecutive AP patients were analyzed. ERFT has no impact on clinical outcomes of hemoconcen-
trated, non-severe or all non-hemoconcentrated AP patients. In hemoconcentrated patients with severe AP (SAP), ERFT was 
accompanied with increased risk of NPPV (odds ratio 5.96, 95% CI 1.57–22.6). Multivariate regression analyses confirmed 
ERFT and hemoconcentration were significantly and independently associated with persistent organ failure and mortality 
in patients with SAP.
Conclusions ERFT is associated with increased rate of NPPV in hemoconcentrated patients with SAP.
Keywords Acute pancreatitis · Fluid therapy · Hemoconcentration · Noninvasive positive-pressure ventilation · Persistent 
organ failure
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Introduction
The severe form of acute pancreatitis (SAP), defined 
as single or multiple persistent organ failure (OF) by 
Revised Atlanta Classification (RAC), carries a mortality 
of 36–50% [1]. The most common OF is respiratory dys-
function and failure [2, 3]. Despite many advances in our 
understanding of the pathophysiology of AP, there remains 
no effective pharmacological treatment [4]. Fluid resusci-
tation is considered the cornerstone of early treatment of 
AP [5, 6], although there are many unanswered questions 
regarding the type of fluid to use, how fast to give it, and 
how best to monitor the response to it [7].
A number of studies have investigated the rate of fluid 
administration in patients with AP. Many clinicians advo-
cate [5, 6] “early aggressive” fluid therapy on the basis 
that this reduces the systemic inflammatory response syn-
drome (SIRS), incidence of OF and hospital length of stay 
(LOS), but the benefits were more pronounced for mild 
than severe cases [8]. Other studies have suggested that 
in patients with predominately mild AP, early aggressive 
fluid therapy is associated with reduced LOS [9, 10] and 
improved composite clinical outcomes [11]. In contrast, 
clinicians advocating a more moderate approach to fluid 
resuscitation argue that pancreatic necrosis is irreversible 
and that a higher volume of fluid given over the first 24 h 
is associated with higher incidence of respiratory dysfunc-
tion/failure, local complications, sepsis, and mortality [3, 
12–14]. A randomized controlled clinical trial of patients 
with predicted SAP had a significantly worse clinical out-
come with rapid fluid expansion [15, 16]. The International 
Association of Pancreatology (IAP)/American Pancreatic 
Association (APA) [6], American College of Gastroenter-
ology (ACG) [5], and Japanese Practice Guidelines [17] all 
recommend aggressive hydration although at different fluid 
rates (Table 1). Given the conflicting low level evidence, 
the American Gastroenterology Association (AGA) Prac-
tice Guidelines [18] only recommend “early goal-directed” 
fluid therapy without providing details for other important 
aspects of fluid therapy. While there is some evidence that 
early goal-directed therapy decreases mortality in severe 
sepsis and septic shock [19], subsequent trials have not 
confirmed this (i.e., ARISE, PROCESS, and PROMISE) 
[20–22]. Many other goals have been proposed [23] and 
while the goal-directed approach is an attractive concept, 
none have been adequately validated in the management 
of patients with AP. In the absence of a proven goal for 
fluid resuscitation, it is not yet possible to recommend a 
goal-directed approach in AP patients.
The most commonly used goals of fluid resuscitation are 
the normalization of urine output and blood pressure [23], 
but this has been shown to risk fluid overload and increased 
mortality [24]. The laboratory marker that shows promise 
as a goal and a guide to fluid therapy in patients with AP 
is hematocrit [25]. Hematocrit is the volume percentage of 
red blood cells in blood, or a marker of hemoconcentra-
tion or hemodilution. Hemoconcentration in AP was first 
described in the 1960s [26]. In 1998, Baillargeon et al. [27] 
reported that an admission serum hematocrit level ≥ 47% 
that did not decrease during the first 24 h was predictive 
of acute necrotic collection (ANC). Subsequent prospective 
studies [28–30] by the same group suggested that an admis-
sion hematocrit level ≥ 44%, especially if it increased at 
24 h, was a significant predictor for both ANC and OF. This 
has been confirmed in a recent study of 1,612 AP patients, 
where admission hematocrit > 44% was a more accurate 
predictor of ANC and persistent OF than other biomark-
ers [31]. A randomized controlled clinical trial of patients 
with predicted SAP had a significantly worse clinical out-
come when hematocrit was decreased to < 35% within 48 h 
of commencing fluid resuscitation, i.e., rapid hemodilution 
[15, 16]. The IAP/APA Practice Guidelines recommend that 
the goal of fluid therapy should be to maintain hematocrit 
levels at 35–44% [6].
In this study, we undertook retrospective analysis of 
prospectively collected data from the largest AP tertiary 
center in China (Supplementary Fig. S1) to determine the 
relationship between early rapid fluid therapy (ERFT), 
hemoconcentration, and clinical outcomes in patients with 
Table 1  Summary of clinical guidelines of aggressive hydration in acute pancreatitis
IAP International Association of Pancreatology, APA American Pancreatic Association, ACG American College of Gastroenterology, AGA 
American Gastroenterology Association, WSES World Society of Emergency Surgery
Guidelines Fluid rate
2013 IAP and APA Goal-directed intravenous fluid therapy with 5–10 ml/kg/h
2013 ACG Aggressive hydration, defined as 250–500 ml/h crystalloid solution
2015 Japanese guideline Short-time rapid fluid resuscitation (150–600 ml/h) depending on the presence of shock and the dehydration level
2018 AGA Goal-directed therapy for fluid management
2019 WSES Fluid overload is known to have detrimental effects, and early fluid resuscitation should be guided by frequent 
reassessment of the hemodynamic status
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AP after general ward admission. The hypothesis was that 
ERFT is associated with increased risk of respiratory dys-
function requiring noninvasive positive-pressure ventila-
tion (NPPV) in hemoconcentrated SAP patients.
Materials and Methods
Study Design and Setting
A retrospective analysis was conducting using the 
STROBE guidelines [32] of the AP database at West China 
Hospital of Sichuan University. This is the largest center 
in China managing patients with AP. The study protocol 
was approved by the Institutional Review Board (No. 247) 
of the hospital, and informed consent was waived. Data 
from consecutive AP patients admitted to the Pancreatitis 
Center between January 1, 2016, and August 31, 2017, 
were prospectively collected into our database (Micro-
soft Access, Redmond, USA) by data managers using 
electronic Heath Information System (Donghua Medical, 
Shenzhen, China). Data regarding fluid therapy were ret-
rospectively collected using International Classification 
of Diseases 10th edition (ICD-10) code K85 for patient 
identification.
Data Collection
Quality assurance, quality control, standard operating proce-
dures, and researcher training were implemented in the study 
process. Retrospective data collection for fluid collection 
was undertaken by two experienced clinical researchers (LL 
and TJ) using a pre-defined pro forma designed by senior 
authors (QX and WH) and audited by clinical leads (LD, 
KJ, and ZL).
Inclusion and Exclusion Criteria
AP was diagnosed by two of three criteria: epigastric abdom-
inal pain, elevated amylase or lipase > 3 times of the upper 
limit of normal, and/or imaging consistent with AP [1]. Con-
firmed AP patients who had symptom onset ≤ 48 h when 
admitted to general wards were included regardless of the 
disease episodes. Exclusion criteria included those in whom 
AP was not the primary admitting diagnosis; ages < 18 
or > 70 years; patients transferred to ICU admission within 
24 h of ward admission; AP due to trauma or pancreatic 
cancer; chronic pancreatitis; pregnancy; advanced comor-
bidities; incomplete data for extraction (for example, lack 
of body weight, height, or computed tomography images).
Fluid and Intensive Care Management
In the West China Hospital, AP patients are initially admit-
ted to the Emergency Department (ED). After confirming the 
diagnosis and initiation of fluid therapy with normal saline 
in the ED, patients are transferred to a general ward. Once 
transferred to the ward, patients have continuation of fluid 
therapy with (normal saline or Ringer’s lactate solution) at 
1–5 ml/kg/h for the first 24 h, with the rate based on pre-
dicted severity of AP and the clinical assessment of hydra-
tion status, rather than based on a pre-defined resuscitation 
protocol. Patients do not routinely receive additional fluid 
as a bolus (e.g., 10–20 ml/kg/h over 30–45 min) unless they 
were shocked, with mean arterial pressure < 65 mm Hg [33]. 
Patients are admitted to a ward-based high-dependency unit 
(HDU) if they meet the criteria for NPPV [34]. Indications 
for NPPV are: patients alert and orientated, able to control 
airway and clear secretion but experiencing tachypnea (res-
piratory rate > 25/min) or dyspnea (use of accessory muscles 
for breathing), or arterial partial pressure of  PaO2 < 60 mm 
Hg, with or without partial pressure of  CO2 > 45 mm Hg 
(measured by Roche Cobas b123 automatic blood gas 
analyzer; Shanghai, China), despite high flow oxygen by 
humidified non-rebreather mask (1060, Teleflex Medical; 
Limerick, PA, USA) at 8 L/min. The NPPV is delivered by 
Respironics V60 in the BiPAP S/T mode (Philips Respiron-
ics,  BiPAP® Vision™; Pittsburgh, PA, USA) with a positive 
end expiratory pressure of 4–6 cmH2O. Patients are admit-
ted to intensive care unit (ICU) for mechanical ventilation, 
renal replacement therapy, and/or the need for continuous 
vasopressors/inotropes.
Study Definitions
“Severity” of AP The actual severity of AP patients was used 
to stratify patients, using the RAC criteria [mild AP (MAP), 
moderately severe AP (MSAP), and SAP] based on the most 
severe grade during period of index hospital admission [1].
“Early” fluid therapy This was the “first 6 h” of fluid therapy 
administered on the general wards, after transfer from ED. 
This did not include the fluid administered in the ED prior 
to transfer.
“Rate” of fluid therapy The rate of fluid infusion was defined 
as “rapid” if it was ≥ 3 ml/kg/h (with “slow” < 3 ml/kg/h), 
based on the average rate of fluid therapy during the first 
6  h of admission on general ward. Thus, ERFT would 
be ≥ 225 ml/h for a 75-kg person over the first 6 h and “early 
slow fluid therapy” (ESFT) < 225 ml/h. The cut-off fluid rate 
of 3 ml/kg/h was taken from ACG Guidelines (≥ 250 ml/h) 
[5].
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Hemoconcentration Hematocrit was also measured at the 
time of admission to the general ward and not admission 
to ED. Hemoconcentration was defined as serum hemato-
crit > 44% [27, 28, 31].
Patients Groups
The patients were stratified into 4 groups based on hema-
tocrit and fluid rate and all in reference to the first 6 h of 
admission to the general wards:
Group A hematocrit ≤ 44% on admission and fluid 
rate < 3 ml/kg/h,
Group B hematocrit ≤ 44% on admission and fluid 
rate ≥ 3 ml/kg/h,
Group C hematocrit > 44% on admission and fluid 
rate < 3 ml/kg/h,
Group D hematocrit > 44% on admission and fluid 
rate ≥ 3 ml/kg/h.
Outcomes
The primary clinical outcome measure was the rate of 
NPPV. We have selected NPPV as the primary endpoint 
because respiratory dysfunction/failure is the most common 
organ system affected, and because we have demonstrated 
that the most frequently noted consequence of ERFT is res-
piratory dysfunction [24]. In our setting, NPPV is the most 
commonly used means of organ support and it is frequently 
used in the general ward setting, and has been shown to 
reduce the need for ICU admission and invasive ventilation 
[34]. Secondary outcomes included persistent OF, multiple 
OF (MOF), HDU admission, ICU admission, local pancre-
atic complications, drainage necrosectomy, overall mortality, 
length of overall hospital stay (LOS), and costs. Definitions 
for etiologies and other study variables are shown in Sup-
plementary Methods.
Statistical Analysis
Baseline parameters and clinical outcomes were compared 
between groups A and B (non-hemoconcentrated: ESFT vs. 
ERFT) or groups C and D (hemoconcentrated: ESFT vs. 
ERFT). Groups A and C (ESFT: non-hemoconcentrated vs. 
hemoconcentrated) were also compared with groups B and 
D (ERFT: non-hemoconcentrated vs. hemoconcentrated). 
Categorical data are expressed as number and percentage 
and compared by 2 test (or Fisher’s exact test). Continuous 
data are presented as median and interquartile range (IQR) 
and compared using Mann–Whitney U test (2 groups) or 
Kruskal–Wallis H test (3 groups) if distribution was skewed. 
Baseline variables with or without clinical severity score 
on ward admission were compared between groups using 
univariate analysis. Those covariates with P value < 0.2 were 
further fitted into: (1) multivariate logistic regression analy-
ses for categorical clinical outcomes and linear regression 
analyses for qualitative clinical outcomes and LOS of MAP 
and MSAP [1], respectively, and expressed as odds ratio 
(OR) with 95% confidence interval (CI); or (2) Cox regres-
sion analyses for predicted hospital discharge and expressed 
as hazard ratios (HR) with 95% CI. In the Cox analysis, days 
for deceased patients are considered as truncated data. A 
two-sided P < 0.05 was considered statistically significant. 
Statistical analyses were performed using  SPSS® 21.0 (IBM, 
Armonk, New York, USA).
Results
Characteristics of Patient Cohort
The algorithm for fluid therapy and patient selection is 
presented in Fig. 1. A total of 912 patients were included 
in the study. The baseline characteristics and clinical out-
comes stratified by RAC severity grades [1] are summarized 
in Table 2: 352 (38.6%) were MAP, 412 (45.2%) MSAP, 
and 148 (16.2%) SAP. The median age was 45 years (range 
19 to 70 years), and 68% were males. Hypertriglyceri-
demia (36.7%) was the leading etiology, followed by biliary 
(23.1%) and alcohol (7.8%), consistent with our recent find-
ings from large cohorts [2, 35, 36]. The median time from 
symptom onset to general ward admission was 24 h (range 
6–48 h), and that from ED to general ward was 6.5 h (range 
4–19.5 h). Of 148 patients with persistent OF, 95 (64%) had 
an onset ≤ 24 h of admission, followed by 44 (29.7%), 3 (2%) 
and 6 (4%) on day 1, 2, and 3 and days ≥ 4, respectively 
(Supplementary Fig. 2). There were 145 [15.9%] respiratory, 
10 [1.0%] circulatory, and 22 [2.4%] renal persistent OF 
with 22 (2.4%) had MOF. There were 157 (17.2%) admitted 
to HDU/ICU. Local pancreatic complications were diag-
nosed in a total of 518 patients: 331 (46.5%) had acute peri-
pancreatic fluid collections (APFC), and 187 (20.5%) had 
ANC. Pancreatic necrosectomy was performed in 43 (6.0%) 
patients. All 27 patients who died had SAP (27/148, 18.2%), 
giving an overall mortality rate of 3.8% (Table 2). 
Baseline Parameters and Clinical Outcomes
Patients with hemoconcentration on admission (n = 313), 
compared with those without hemoconcentration (n = 599; 
Supplementary Table 1), were significantly younger (median 
43 vs. 46 years, P <0.001), more likely to be male (86.6% 
vs. 58.2%, P <0.001), and had increased body mass index 
(26 vs. 24.7 kg/m2, P < 0.001), Charlson comorbidity index 
(median score 2 vs. 1, P < 0.05), and were associated with 
more severe clinical severity scores (SIRS, Glasgow, Acute 
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Physiology and Chronic Health Evaluation II and Sequential 
Organ Failure Assessment scores; all P < 0.001). In regard 
to clinical outcomes, the incidence of APFC, rate of necro-
sectomy, and LOS were similar between those with and 
without hemoconcentration. All other clinical outcomes of 
interest were significantly worse in the hemoconcentrated 
patients (Supplementary Table 2), including single persistent 
OF, MOF, ICU admission, respiratory support, ANC, and 
mortality.
Clinical Outcomes of Hemoconcentrated Patients 
Between Different Fluid Rates
Furthermore, there was no difference in hospital LOS in 
MAP (Supplementary Table 3a); there were no differences 
all clinical outcomes of interest in MSAP (Supplementary 
Table 3b). In SAP patients, there was no difference in base-
line parameters (including age, gender, body mass index, 
Charlson comorbidity index, time to admission, etiology, 
and admission clinical severity scoring system) and severity 
of acute respiratory distress syndrome (ARDS) as per Berlin 
definition [37] when admitted at general wards (all P > 0.09; 
Table 3); however, there was significantly higher respiratory 
support rate (OR 5.01, 95% CI [1.30, 19.3], P = 0.019), and 
this was mostly attributed to higher rate of NPPV use (OR 
5.96, 95% CI [1.57, 22.6], P = 0.009; Table 4). And there 
was significantly reduced predicted hospital discharge (HR 
0.62 [0.20, 1.87], P = 0.030), indicating significantly longer 
LOS in SAP (Table 4), while rate of persistent OF, MOF, 
local complications, necrosectomy, and mortality were simi-
lar (all P > 0.19, Table 4).
After adjusting for different baseline parameters, sub-
sequent analyses showed that there were no differences in 
clinical outcomes in all severity categories of non-hemocon-
centrated patients between ESFT and ERFT (Supplementary 
Table 4a-c; all P > 0.15).
There were no significant differences in baseline param-
eters of SAP patients between non-hemoconcentrated and 
hemoconcentrated groups in ESFT or in ERFT. None of 
the clinical outcomes between non-hemoconcentrated and 
Fig. 1  Fluid therapy and patient 
selection process of acute 
pancreatitis. Patients selection 
process of the study. AP acute 
pancreatitis, MAP mild acute 
pancreatitis, MSAP moderate 
severe acute pancreatitis, SAP 
severe acute pancreatitis. *Ini-
tial fluid therapy
Patients included in the study  
n = 912


















Patients excluded: n = 3876
Symptom onset to admission > 48 hours: 
1221 
AP was not the primary admitting 
diagnosis: 841 
Age < 18 or > 70 years old: 934 
Trauma, chronic pancreatitis, pancreatic 
cancer as aetiologies or pregnancy: 600 
Advanced co-morbidities: 219 
Incomplete data: 61 
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hemoconcentrated groups were significantly different fol-
lowing ESFT (Supplementary Table 5). Compared with non-
hemoconcentrated patients, the hemoconcentrated patients 
were associated with prolonged predicted hospital discharge 
(HR 0.11 [0.18, 0.68], P = 0.017) following ERFT (Supple-
mentary Table 6).
Fluid Therapy Rate and Volume
As expected and based on the definitions, there were signifi-
cant differences in fluid rate between the four groups for those 
with and without hemoconcentration (Supplementary Fig. 3). 
The actual total fluid therapy volume given during the first 
24 h was, as expected, significantly higher in patients with 
MSAP and SAP who received rapid fluid therapy (Supplemen-
tary Fig. 3b, c), but not in patients with MAP (Supplementary 
Fig. 3a).
Table 2  Baseline characteristics and clinical outcomes of overall included patients
MAP mild acute pancreatitis, MSAP moderately severe acute pancreatitis, SAP severe acute pancreatitis, IQR interquartile range, SIRS systemic 
inflammatory response syndrome, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, 
OF organ failure, MOF multiple organ failure, HDU high-dependency unit, ICU intensive care unit, ANC acute necrotic collection, LOS length 
of stay
a Indicates χ2 (or Fisher’s exact test) for qualitative data and Kruskal–Wallis H test for quantitative data
b P < 0.05, severe versus mild or moderate
c P < 0.05, mild versus moderate
d P < 0.05, between any two groups
e Data from deceased patients are removed from the analysis
Parameters Total (n = 912) MAP (n = 352) MSAP (n = 412) SAP (n = 148) P  valuea
Demographics
Age, years, median (IQR) 45 (38–51) 44 (39–51) 45 (38–51) 46 (41–52) 0.004b
Gender, male (%) 620 (68.0) 234 (66.7) 285 (69.2) 101 (68.2) 0.437
Body mass index, kg/m2 median (IQR) 25.3 (23.0–27.7) 25.3 (22.9–27.7) 24.9 (22.8–27.3) 26.3 (24.0–28.4) < 0.001b
Charlson comorbidity index, median (IQR) 1 (0–2) 2 (0–2) 1 (0–2) 1 (0–2) 0.593
Etiology
 Biliary 211 (23.1) 63 (17.9) 112 (27.2) 36 (24.3) 0.002c
 Hypertriglyceridemia 335 (36.7) 134 (38.2) 140 (34.0) 61 (41.2) 0.229
 Alcoholics 71 (7.8) 31 (8.9) 26 (6.3) 14 (9.5) 0.241
 Others 295 (32.3) 124 (35.2) 134 (32.5) 37 (25.0) 0.205
Clinical scoring systems
SIRS, median (IQR) 2 (1–2) 1 (1–2) 2 (1–2) 3 (2–3) 0.009d
Glasgow, median (IQR) 1 (0–2) 1 (0–1) 1 (0–2) 2 (2–3) < 0.001d
APACHE II, median (IQR) 4 (2–6) 3 (2–5) 4 (2–6) 7 (5–10) < 0.001d
SOFA, median (IQR) 0 (0–1) 0 (0–0) 0 (0–1) 2 (0–3) < 0.001d
Clinical outcomes
Single persistent OF
 Respiratory (%) 145 (15.9) 0 0 145 (98.0) < 0.001d
 Circulatory (%) 10 (1.0) 0 0 10 (6.8) < 0.001b
 Renal (%) 22 (2.4) 0 0 22 (14.9) < 0.001b
MOF (%) 22 (2.4) 0 0 22 (14.9) < 0.001b
HDU/ICU admission (%) 157 (17.2) 0 35 (8.5) 122 (82.4) < 0.001d
Respiratory support (%) 133 (18.7) 0 10 (2.4) 122 (82.4) 0.013d
Local complication
 Acute peripancreatic fluid collection (%) 331 (46.5) 0 234 (56.8) 97 (65.5) < 0.001d
 ANC (%) 187 (20.5) 0 128 (31.3) 59 (39.9) < 0.001d
Necrosectomy (%) 43 (6.0) 0 20 (4.9) 23 (15.5) 0.017d
Mortality (%) 27 (3.8) 0 0 27 (18.2) < 0.001b
Hospital LOS, median (IQR)e 10 (7–14) 8 (6–10) 10 (7–14) 17 (13, 24) < 0.001d
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Multivariate Logistic Regression Analyses 
and Sensitivity Analyses
In the multivariate logistic regression analyses, 6 (includ-
ing age, time to admission, body mass index, referral, 
hemoconcentration, and ERFT) of 9 independent covari-
ables were associated with persistent OF, 1 (referral) with 
ANC, 4 (Charlson comorbidity index, body mass index, 
hemoconcentration, and ERFT) with mortality (Table 5). 
Admission hemoconcentration and ERFT were signifi-
cantly associated with persistent OF and mortality, but 
not ANC (Table 5). 
When restricted to patients admitted < 24 h after symp-
toms onset, hemoconcentration and ERFT were significantly 
associated with persistent OF, and only hemoconcentration 
was significantly associated with ANC (Table 6). Mortal-
ity was removed from analysis as only 8 deaths in 41 SAP 
patients.
When restricted to patients admitted directly to West 
China Hospital, excluding those referred from other hos-
pitals, only admission hemoconcentration and ERFT were 
associated with persistent OF and none of the other 9 covari-
ables were significantly associated with ANC (Table 7). 
Mortality was removed from analysis as only 4 deaths in 
40 SAP patients.
Discussion
The key finding of this study is that hemoconcentrated SAP 
patients who received ERFT had an increased risk of res-
piratory dysfunction (requiring NPPV) and had an increased 
LOS. This was not found in hemoconcentrated MAP and 
MSAP patients. Multivariate logistic regression analyses 
confirmed that ERFT and hematocrit (on admission to gen-
eral wards) were significantly associated with persistent OF 
and mortality, but not ANC. The important clinical implica-
tion from this study is that ERFT should be used with cau-
tious and tailored to the patient’s requirements in predicted 
SAP patients who remain hemoconcentrated after initial 
fluid therapy [38–40]. The unsolved challenge is how to reli-
ably determine an individual patient’s fluid requirements and 
how best to monitor the response to what is given [41].
In this study, we defined hemoconcentration as admission 
hematocrit level > 44%, based on previous studies [28, 29, 
31]. Our results show that patients with hemoconcentration 
Table 3  Comparison of baseline 
parameters and ARDS level in 
hemoconcentrated SAP patients 
between different fluid rates
ARDS acute respiratory distress syndrome, SAP severe acute pancreatitis, IQR interquartile range, SIRS 
systemic inflammatory response syndrome, APACHE II Acute Physiology and Chronic Health Evaluation 
II, SOFA Sequential Organ Failure Assessment
a Indicates χ2 or Fisher’s exact test for qualitative data and Mann–Whitney U test for quantitative data






 Age, years, median (IQR) 46 (41, 53) 46 (38, 52) 0.580
 Gender, male (%) 23 (79.3) 36 (73.5) 0.599
 Body mass index (kg/m2), median (IQR) 26.1 (23.1, 28.1) 26.8 (24.2, 30.0) 0.379
 Charlson comorbidity index, median (IQR) 1 (0–2) 1 (0–2) 0.496
 Time to admission (h), median (IQR) 24 (21–24) 24 (17–24) 0.438
Etiology
 Biliary (%) 12 (41.4) 13 (26.5) 0.213
 Hypertriglyceridemia (%) 8 (27.6) 20 (40.9) 0.329
 Alcoholic (%) 0 6 (12.2) 0.079
 Others (%) 9 (31.0) 10 (20.4) 0.413
Clinical scoring systems
 SIRS, median (IQR) 3 (2–3) 3 (2–3) 0.486
 Glasgow, median (IQR) 2 (2–3) 3 (2–4) 0.091
 APACHE II, median (IQR) 8 (6–11) 8 (7–14) 0.685
 SOFA, median (IQR) 2 (0–3) 2 (1–4) 0.152
ARDS level at admission (%)
 Mild (200–300) 9 (33.3) 9 (19.6) 0.188
 Moderate (100–200) 6 (22.2) 13 (28.3) 0.570
 Severe (≤ 100) 0 2 (4.3) 0.272
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at ward admission had significantly higher baseline clinical 
severity scores and worse clinical outcomes (persistent OF, 
MOF, ANC, and mortality), consistent with the published 
literature [28, 29, 31]. The argument for ERFT is that hemo-
concentration increases blood viscosity and flow resistance 
[42] and that correcting this with early aggressive fluid 
Table 4  Comparison of clinical outcomes in hemoconcentrated SAP patients between different fluid rates
Bold values indicate statistical significance P < 0.05
SAP severe acute pancreatitis, CI confidence interval, ESFT early slow fluid therapy, ERFT early rapid fluid therapy, OF organ failure, MOF 
multiple organ failure, HDU high-dependency unit, ICU intensive care unit, NPPV noninvasive positive-pressure ventilation, IMV invasive 
mechanic ventilation, ANC acute necrotic collection, LOS length of stay, IQR interquartile range
a Indicates χ2 (or Fisher’s exact test) for qualitative data and Mann–Whitney U test for quantitative data
b Odds ratio for qualitative data and hazard ratio for quantitative data (deceased patients are considered as truncated data)
c Indicates multivariate logistic regression model for qualitative data and Cox proportional hazards model quantitative data, respectively, after 
adjusting baseline variables from the univariate analysis with P < 0.2
d In ESFT group, 14 only had NPPV, 4 had NPPV and then IMV, 2 had IMV without prior NPPV; in ERFT group, 30 only had NPPV, 11 had 
NPPV and then IMV, 4 had IMV without prior NPPV
e Predicted hospital discharge is used to calculate the estimate (deceased patients are considered as truncated data)










 Respiratory (%) 27 (93.1) 48 (98.0) 0.281 3.33 (0.27, 41.5) 0.350
 Circulatory (%) 1 (3.4) 9 (18.4) 0.057 4.39 (0.48, 40.0) 0.189
 Renal (%) 5 (17.2) 11 (22.4) 0.582 0.64 (0.15, 2.81) 0.556
MOF (%) 4 (13.8) 14 (28.6) 0.134 1.59 (0.36, 6.99) 0.542
HDU/ICU admission (%) 23 (79.3) 43 (87.8) 0.318 1.89 (0.52, 6.89) 0.333
Respiratory support (%)d 20 (69.0) 45 (91.8) 0.009 5.01 (1.30, 19.3) 0.019
 NPPV (%) 18 (62.1) 41 (83.7) 0.032 5.96 (1.57, 22.6) 0.009
 IMV (%) 6 (20.7) 15 (30.6) 0.340 1.48 (0.43, 5.08) 0.530
Local complication
 Acute peripancreatic fluid collection (%) 21 (72.4) 36 (73.5) 0.919 0.89 (0.30, 2.64) 0.832
 ANC (%) 13 (44.8) 22 (44.9) 0.995 0.99 (0.37, 2.50) 0.925
Necrosectomy (%) 6 (20.7) 5 (10.2) 0.198 0.48 (0.13, 1.84) 0.285
Mortality (%) 7 (24.1) 10 (20.4) 0.700 0.29 (0.09, 0.89) 0.386
Hospital LOS, median (IQR)e 17 (10-22) 21 (13-29) 0.068 0.62 (0.20, 1.87) 0.030
Table 5  Multivariate analyses for persistent organ failure, acute necrotic collection, and mortality in all patients
Bold values indicate statistical significance P < 0.05
Variable Persistent organ failure Acute necrotic collection Mortality
Estimate P Estimate P Estimate P
Age (years)a 1.04 (1.01, 1.05) 0.003 1.00 (0.98, 1.01) 0.605 1.04 (1.00, 1.09) 0.079
Gender 0.92 (0.58, 1.46) 0.733 1.04 (0.70, 1.54) 0.844 0.49 (0.20, 1.22) 0.126
Charlson comorbidity  indexa 0.86 (0.73, 1.03) 0.099 0.97 (0.84, 1.12) 0.674 0.66 (0.44, 0.98) 0.039
Time to admission (h)a 1.03 (1.01, 1.04) 0.007 0.99 (0.98, 1.01) 0.372 1.03 (0.99, 1.06) 0.149
Body mass index (kg/m2)a 1.09 (1.03, 1.15) 0.002 1.04 (0.99, 1.08) 0.134 1.15 (1.04, 1.26) 0.005
Etiology 0.88 (0.65, 1.18) 0.381 1.10 (0.87, 1.39) 0.425 0.89 (0.50, 1.59) 0.691
Referral 3.38 (2.08, 5.51) < 0.001 2.26 (1.56, 3.28) < 0.001 3.02 (0.97, 9.41) 0.057
Hemoconcentration 2.48 (1.63, 3.76) < 0.001 1.40 (0.98, 2.00) 0.061 3.95 (1.65, 9.48) 0.002
ERFT 2.59 (1.74, 3.85) < 0.001 1.31 (0.90, 1.85) 0.130 2.39 (1.05, 5.44) 0.039
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therapy will improve organ perfusion (e.g., pancreas, lung, 
kidneys) and clinical outcomes of AP [28, 29]. Although 
oxygen-carrying capacity of the blood is reduced during 
hemodilution by fluid therapy, there are limits to the com-
pensatory mechanisms (increased cardiac output and tissue 
oxygen extraction) with extreme hemodilution [42]. Exper-
imental studies have suggested that both hemoconcentra-
tion and rapid hemodilution are associated with increased 
severity of the underlying diseases [43, 44]. A randomized 
clinical trial has demonstrated that rapid hemodilution was 
associated with increased sepsis and mortality in patients 
with predicted SAP [16]. The findings of the present study 
are consistent with this trial as ERFT in hemoconcentrated 
SAP patients was associated with a significant increased 
respiratory dysfunction (and need for NPPV) and LOS even 
after adjustment for differences in baseline clinical sever-
ity scores (including SIRS, Glasgow, Acute Physiology and 
Chronic Health Evaluation II and Sequential Organ Failure 
Assessment scores). The most common OF is ARDS, and 
the onset of persistent OF is often early (with 60% in the first 
day of admission) [2, 45, 46]. Given that ARDS is already 
present or is likely to occur in the majority of patients within 
the first 24 h, ERFT might be expected to worsen the sever-
ity of ARDS. Patients who are hypovolemic and without 
significant capillary leak will likely benefit from early and 
rapid fluid resuscitation, but by the time capillary leak has 
developed (which contributes to ARDS development) addi-
tional fluids will increase interstitial fluid volume (edema) 
and cause worsening ARDS. In West China Hospital, it is 
established practice to use NPPV to manage patients with 
early ARDS or at risk of ARDS [34], and it is administered 
on the basis of standard criteria. In this study, it was found 
that there was an increased requirement for NPPV in patients 
Table 6  Multivariate analyses 
for persistent organ failure, 
acute necrotic collection in 
patients of admission < 24 h
Bold values indicate statistical significance P < 0.05
Variable Persistent organ failure Acute necrotic collection
Estimate P Estimate P
Age (years)a 1.03 (0.99, 1.07) 0.106 1.00 (0.97, 2.11) 0.760
Gender 1.50 (0.60, 3.76) 0.391 1.12 (0.60, 2.11) 0.726
Charlson comorbidity  indexa 1.08 (0.79, 1.47) 0.653 1.19 (0.96, 1.49) 0.119
Time to admission (h)a 1.12 (1.04, 1.21) 0.004 0.96 (0.90, 1.01) 0.121
Body mass index (kg/m2)a 1.05 (0.95, 1.16) 0.328 1.04 (0.97, 1.13) 0.275
Etiology 1.26 (0.74, 2.16) 0.392 1.43 (0.97, 2.11) 0.071
Referral 2.03 (0.96, 4.28) 0.063 2.11 (1.23, 3.63) 0.007
Hemoconcentration 5.74 (2.63, 12.5) < 0.001 1.77 (1.01, 3.09) 0.045
ERFT 3.36 (1.58, 7.14) 0.002 1.44 (0.82, 2.53) 0.202
Table 7  Multivariate analyses 
for persistent organ failure, 
acute necrotic collection in 
primarily admitted patients
Age, gender (male vs. female), Charlson comorbidity index, time to admission, body mass index, etiol-
ogy (hypertriglyceridemia, biliary, alcoholic, others), transfer (yes vs. no), hemoconcentration (yes, hema-
tocrit > 44% vs. no, ≤ 44%), fluid rate (fast, ≥ 3 ml/kg/h vs. slow, < 3 ml/kg/h) were included in multivariate 
logistic regression analysis
Bold values indicate statistical significance P < 0.05
ERFT early rapid fluid therapy
a Continuous variable
Variable Persistent organ failure Acute necrotic collection
Estimate P Estimate P
Age (years)a 1.01 (0.97, 1.05) 0.836 0.98 (0.95, 1.01) 0.286
Gender 0.44 (0.16, 1.22) 0.116 1.01 (0.50, 2.04) 0.974
Charlson comorbidity  indexa 0.98 (0.69, 1.39) 0.898 1.11 (0.87, 1.41) 0.418
Time to admission (h)a 1.02 (0.97, 1.06) 0.471 0.99 (0.96, 1.02) 0.592
Body mass index (kg/m2)a 1.09 (0.96, 1.24) 0.177 1.04 (0.95, 1.13) 0.419
Etiology 1.13 (0.59, 2.18) 0.715 1.31 (0.85, 2.03) 0.225
Hemoconcentration 2.95 (1. 51, 7.54) 0.024 1.13 (0.59, 2.20) 0.709
ERFT 3.12 (1.28, 7.58) 0.012 1.54 (0.81, 2.92) 0.187
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receiving ERFT (compared with ESFT) even though the 
ARDS severity was comparable between these two groups.
By avoiding invasive ventilation in the majority of 
patients, NPPV can be an effective way to improve gas 
exchange and avoid complications associated with endotra-
cheal intubation and mechanical ventilation in selected 
patients with ARDS [47–49]. It may be the most effective 
option for the initial treatment for all categories of ARDS 
secondary to AP as long as no contra-indication exists [34].
In hemoconcentrated SAP patients of our study, there 
was no difference in severity of ARDS [37] at ward admis-
sion between those receiving ERFT and ESFT. But there 
was a significantly higher rate of NPPV use in the ERFT 
group. This difference may be due to a significantly faster 
rate of fluid therapy during the first 6 h and/or a higher 
total fluid volume during 24 h in the ERFT group (Sup-
plementary Fig. 3). The finding is consistent with studies 
which showed that rapid and high volume fluid therapy 
increases the risk of pulmonary edema and exacerbates 
respiratory failure in AP [13, 24]. Our study has several 
limitations. The fluid management data were collected ret-
rospectively, and there was a lack of data for fluid given 
prior to admission to the general ward. The hematocrit 
prior to fluid therapy in ED was also not available. How-
ever, the prospective data we have collected indicate that 
a mean of approximately 1000 ml fluid was given in the 
ED prior to general ward admission. Another potential 
confounder in this study was that patients with hemocon-
centration may not have received enough fluid, despite no 
difference between hemoconcentrated and non-hemocon-
centrated patients in regard to time to admission and vol-
ume of fluid given. Hemoconcentrated patients had more 
severe disease and were therefore at greater risk of respira-
tory dysfunction such that ERFT may be just an associa-
tion and not a cause. With this study design, it is not pos-
sible to absolutely prove that ERFT caused an increased 
requirement of NPPV. Lastly, this was a single-center 
cohort composed by high proportion of patients with a 
hyperlipidemia as etiology of AP [2, 35, 36], which may 
limit the generalizability of our findings.
In conclusion, this study has shown that ERFT in hemo-
concentrated patients with SAP patients is associated with 
increased use of NPPV and longer LOS. This was not the 
case in hemoconcentrated patients with MAP and MSAP 
or in non-hemoconcentrated patients in all three grades of 
severity. Because of the risks identified in this study, a bet-
ter understanding of why ERFT is associated with worse 
clinical outcomes in hemoconcentrated patients with SAP 
is important. Appropriately designed randomized clinical 
trials are urgently needed to determine how fluid therapy 
should be given in patients with predicted severe disease 
and hemoconcentration.
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